China Health Care Data Insights: Online sales of GLP-1 therapies remain robust; Mazdutide saw upward momentum in salesIssuing time:2025-07-31 00:00 Online sales of GLP-1 therapies continued to accelerate across major e-commerce platforms in China. According to DataBurning's tracking, in the 30-day period ending 2025/7/13: [Rybelsus] (semaglutide for glycemic control, Novo Nordisk) generated ~RMB 140 mln in GMV across major e-commerce platforms in China, representing a 177% y/y increase. GMV for 25H1 has already matched the full-year total for 2024. [Wegovy] (semaglutide for weight loss, Novo Nordisk) recorded over RMB 7 mln in GMV. Novo Nordisk received regulatory approval for Wegovy as a weight loss treatment in China, and since its launch in November 2024, Wegovy has achieved cumulative GMV of ~RMB 35 mln. [Zepbound] (tirzepatide for weight loss, Eli Lilly) achieved GMV of over RMB 30mln. Eli Lilly received regulatory approval for Zepbound as a weight loss treatment in China, and since its launch in January 2025, Zepbound has achieved cumulative GMV of nearly RMB 80 mln. [Mazdutide / Xinermei] (Innovent Biologics) recorded over RMB 3mln in GMV. *On 2025/6/27, Mazdutide (commercial name: Xinermei), co-developed by Innovent Biologics and Eli Lilly, was officially approved in China for chronic weight management in adults with overweight or obesity. The product is now available on major e-commerce platforms.
Article classification:
Topical Insights
|